©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Pediatr. Aug 8, 2016; 5(3): 281-287
Published online Aug 8, 2016. doi: 10.5409/wjcp.v5.i3.281
Published online Aug 8, 2016. doi: 10.5409/wjcp.v5.i3.281
Drug delivery interfaces: A way to optimize inhalation therapy in spontaneously breathing children
Arzu Ari, Department of Respiratory Therapy, Georgia State University, Atlanta, GA 30303-3083, United States
Author contributions: Ari A is the sole author of this manuscript.
Conflict-of-interest statement: Ari A serves on the advisory board of Bayer Pharmaceuticals.
Correspondence to: Arzu Ari, FAARC, PhD, PT, RRT, Department of Respiratory Therapy, Georgia State University, 140 Decatur Street Suite 1228, Atlanta, GA 30303-3083, United States. arzuari@hotmail.com
Telephone: +1-404-4131269 Fax: +1-404-4131230
Received: March 20, 2016
Peer-review started: March 22, 2016
First decision: April 20, 2016
Revised: May 3, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: August 8, 2016
Processing time: 141 Days and 19.2 Hours
Peer-review started: March 22, 2016
First decision: April 20, 2016
Revised: May 3, 2016
Accepted: July 11, 2016
Article in press: July 13, 2016
Published online: August 8, 2016
Processing time: 141 Days and 19.2 Hours
Core Tip
Core tip: Many interfaces exist for aerosol drug delivery to spontaneously breathing children and inhalation therapy with different interfaces has become an important topic of interest among clinicians. However, clinicians usually focus on selecting the right drug-device combination and often overlook the importance of interface selection that lead to suboptimal drug delivery and therapeutic response in neonates and pediatrics. This paper provides a critical assessment of drug delivery interfaces used for the treatment of children with pulmonary diseases by emphasizing advantages and problems associated with their use during inhalation therapy.